By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Phone: n/a Fax: n/a


AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.

Key Statistics

Ownership: Public

Web Site: AbbVie
Symbol: ABBV


Company News
Detailed Results From Biogen Idec, Inc. (Massachusetts) (BIIB) And AbbVie (ABBV)’s Pivotal Phase 3 Decide Study Further Define The Efficacy And Safety Profile Of ZINBRYTA™ (Daclizumab High-Yield Process) 9/12/2014 10:51:06 AM
AbbVie (ABBV)-Backed Virobay Inc. Lines Up $50 Million IPO 9/11/2014 6:42:50 AM
AbbVie (ABBV)'s Phase 3 Trial Of Humira Meets Primary Endpoint 9/11/2014 6:24:20 AM
AbbVie (ABBV), Teva Pharmaceutical Industries Limited (TEVA) Illegally Blocked Generic Version Of AndroGel: Federal Trade Commission 9/9/2014 5:50:47 AM
A Look Into AbbVie (ABBV)’s $1 Billion Spending Spree 9/8/2014 6:28:06 AM
AbbVie (ABBV) To Present At Morgan Stanley (MST) Global Healthcare Conference 9/5/2014 12:24:51 PM
Google Inc.'s Startup Calico Forges Pact With AbbVie (ABBV), New R&D Facility In San Francisco 9/3/2014 11:50:47 AM
AbbVie (ABBV) Hands Over $275 Million Upfront For Infinity Pharmaceuticals Inc. (INFI)’s Blood Cancer Drug; Deal Could Be Worth $805 Million 9/3/2014 6:20:46 AM
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study 8/28/2014 6:09:13 AM
AbbVie (ABBV) Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards 8/18/2014 9:25:01 AM